Trodusquemine
Navigation Links
Trodusquemine in Medical News
PLYMOUTH MEETING, Pa., Sept. 10 /PRNewswire-FirstCall/ -- Genaera
Corporation (Nasdaq: GENR ) today announced the formation of its
Trodusquemine Scientific Advisory Board (the "SAB"), consisting of leading
experts in the areas of obesity, diabetes and metabolic disorders, to
provide guidance ...
Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust
...tinued listing, which requires a minimum bid price for the Company's common stock of $1.00. About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...Genaera Corporation Announces Results of Special Meeting of Stockholders
...ove a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution). About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors
...able before making any voting or investment decision with respect to the Plan of Dissolution. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...Genaera Corporation Implements Cash Conservation Plan
...order to maintain the ability to pursue business development strategies for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Gen...ely $8.1 million. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical t...Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
...o its Form 10-K which was filed on March 3, 2009 with the Securities and Exchange Commission. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...Genaera Corporation Announces 2008 Financial Results
...rease in clinical and third-party contract research expenses related to the trodusquemine (MSI-1436) program for the treatment of type 2 diabetes and obesity and an ...mber 31, 2008. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical t...Genaera to Present at BIO CEO & Investor Conference
...he treatment of type 2 diabetes and obesity, on Tuesday, February 10, 2009 at 2:15 p.m. (ET). About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
... This panel presentation is being webcast at: www.wsw.com/webcast/rbc95/panel6 About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...Genaera to Present at Therapeutic Area Partnerships 2008
...6 for the treatment of type 2 diabetes and obesity on Tuesday, November 4, 2008 at 4:20 p.m. (ET). About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...Trodusquemine in Medical Technology
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
-Cohort 1 Data Promising for Type 2 Diabetes- PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Ge...Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
- Subcutaneous Administration of MSI-1436 in DIO Rats Highlighted - PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the tre...Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-...PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. MSI-1436 is a novel inhibitor of ...
PLYMOUTH MEETING, Pa., July 25 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced interim Phase 1 safety and pharmacokinetic (PK) data and new preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesit...
PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, du...
PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Sci...
New data supports recent IND and forms foundation for upcoming clinical programs PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), G...
Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
- Second filing provides opportunity for additional indications and increased potential market - PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that the investigational new drug (IND) application submitted to...Study in Overweight and Obese Type 2 Diabetics to Assess Safety and Pharmacokinetics in addition to Specialized Secondary Endpoints PLYMOUTH MEETING, Pa., Jan. 17 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-...
Trodusquemine in Biological Technology
Genaera Receives Non-Compliance Notice from Nasdaq
...Company intends to file a certificate of dissolution and delist its common stock from Nasdaq. About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...Genaera to Present at BIO-Europe 2008
...ientific Officer, will present a company overview on Tuesday, November 18, 2008 at 11:00 a.m. CET. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is...Genaera Corporation Announces Second Quarter Financial Results
...ases in research and clinical costs related to the trodusquemine (MSI-1436) program for the treatment of obesity an...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ...Genaera Corporation Elects Paul K. Wotton to Board of Directors
...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...Genaera Corporation to Present at BIO Business Forum
...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...Genaera Corporation Announces First Quarter Financial Results
...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...Genaera Corporation Announces 2007 Financial Results
...uring, research and personnel costs related to the trodusquemine (MSI-1436) program for the treatment of type 2 dia...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ......focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. ...
Genaera Corporation Announces Third Quarter Financial Results
...emain on track with plan. Positive interim Phase 1 trodusquemine data announced in the quarter is another example o...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...Genaera to Present at Biotech 2007 and BIO InvestorForum
...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...Other TagsStainedPfuPfuOther Contentsconstipationconstipationconstipationcontracturecontactcontactcontactcontactcontactcontactcontactcontactcontactcontagiouscontagiouscontagiouscontagiousconsciousconsciousconsciousconsciousconsciousconvulsioncontraindicationsmediummediummediummediummediummediummediummediummedium
StainedPfuToughestSuperoxideRenillaInterchangeableArchivedBeaconsColoniesEfficienciesPonasteroneUniformityImmunolabelingAllelic
(Date:12/2/2009)...cember 2, 2009Ninety-six percent of low-income mot...based distrust indicated a strong general feeling ...eral distrust towards men did not prevent them fro...elationship. Furthermore, the union was often late...spite their prior assertions of distrust and insec...
(Date:12/2/2009)...TYHow do fruit flies get high cholesterol and beco...iet that,s too rich in fats. , More importantly,...of Utah human geneticist, fruit flies use the same...roper balances of cholesterol and a key form of st... mean that as researchers try to learn more about ...
(Date:12/2/2009)... MyCareTeam, Inc., a leading vendor of ..., has released the newest version of its software ...on, congestive heart failure and weight management... monitoring features. , ..., Inc., a leading vendor of Internet-based chronic...
(Date:12/2/2009)..., SAN DIEGO, Dec. 2 US F...lier of Farming, Nursery and Wellness products, is...e365(TM) products at the Cook,sware A,faire in Oak..., 2009. ,, For additional information, contact ...90-FARMS or visit http://cookswareafaire.com ,...
(Date:12/2/2009)...edia Advisory for Thursday, Dec. 3 ,, Head of...cheon Meeting of Army Wounded Warriors; Army Embra...just ,, WASHINGTON, Dec. 2 /PRNewswire-USNewsw...tional Organization on Disability: ,, WHAT: W...y Wounded Warrior (AW2) program,s National Organiz...
Breaking Medicine News(10 mins):Health News:Latest epidemic? High cholesterol, obesity in fruit flies 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 3Health News:MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure 2Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Wounded Vets, CAREER Counselors Gather in Washington as Obama Announces Afghanistan Troop Buildup 2[0] Distrust of men doesn't stall low-income mothers' romantic unions[0] Latest epidemic? High cholesterol, obesity in fruit flies[0] MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure [0] US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo[0] Wounded Vets, CAREER Counselors Gather in Washington as Obama Announces Afghanistan Troop Buildup
(Date:12/2/2009)...witch, before the thought telling it to flex can r...ed an ion channelmust open in the surface of each ...s that spur the cell to action. New research* at t...(NIST) has allowed scientists to observe ion chann..., potentially offering insights for future drug de...
(Date:12/2/2009)...of Salamanca and another from Yale University have...behaviour of Acanthodactylus beershebensis , a li...t. According to the study, these reptiles move les... are under pressure from predators. , Many theor... now there had been very few experimental trials a...
(Date:12/1/2009)...fferent feeding strategies. A large proportion of...are generalist predators feeding on other small an...er, are "herbivorous". This is not to say that th...s consist of plant-derived matter. For example, so...ttract ants, called extra-floral nectar; others fe...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Lizards change their diet to avoid predators 2Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2Health Club Media Network Adds New York Health 26 Racquet Club 53326 1Health Club Media Network Adds New York Health 26 Racquet Club 53326 2Cutting Edge iPhone 28TM 29 iPod 28R 29 Touch Apps Improve Quality of Life for Those With Celiac Coeliac 26 Food Allergies 53324 1Cutting Edge iPhone 28TM 29 iPod 28R 29 Touch Apps Improve Quality of Life for Those With Celiac Coeliac 26 Food Allergies 53324 2United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 1United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 2United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 3United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 4United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 5United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 6United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 7United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 8United Therapeutics Corporation Reports Second Quarter 2009 Financial Results 53323 9| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |